EC Number   |
Protein Variants |
Reference |
|---|
    1.6.5.2 | C609T |
during cardiopulmonary bypass, interleukin-6 concentrations are increased in NQO1 T carriers compared to T non-carriers, i. e. non-laminar flow during during cardiopulmonary bypass is more deleterious in patients with NQO1 T carriers |
691669 |
| 1.6.5.2 | C609T |
natural polymorphism which may affect amrubicin-related pharmacokinetics and clinical outcomes in lung cancer treatment. At a dose of 40 mg/m2, the T/T genotype exhibits a tendency toward a relationship with decreased concentrations of amrubicinol on days 2 and 4 of treatment. The genotype also shows a significant decrease of hematological toxicities |
744742 |
| 1.6.5.2 | C609T |
no significant differences between distributions of NQO1 C609T genotypes in patients with prostate cancer and controls |
684474 |
| 1.6.5.2 | E77A |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
-, 743659 |
| 1.6.5.2 | E77K |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
743659 |
| 1.6.5.2 | E77L |
site-directed mutagenesis, almost inactive mutant |
743659 |
| 1.6.5.2 | E77M |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
743659 |
| 1.6.5.2 | G115F |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
743659 |
| 1.6.5.2 | G115I |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
743659 |
| 1.6.5.2 | G118F |
site-directed mutagenesis, the mutant shows highly reduced activity compared to wild-type |
743659 |
